drugset / Trial / NCT04592029
TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC
NaSingle-groupOpen-labelTreatment
Summary
This study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization (TACE) combined with sintilimab and bevacizumab in patients with unresectable intermediate or advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2020-09-27
- Primary completion
- 2022-06-30
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Sintilimab | Monoclonal antibody | 200 mg/kg | Intravenous |